The main risks are a temporary resurgence of GI side effects (nausea, constipation, diarrhea), temporary appetite suppression reduction during the low-dose titration phase, and a short-term weight loss pause as tirzepatide builds toward therapeutic levels
Every milliliter of solution now contains 5mg of tirzepatide
Diet and exercise alone: Typically produces 3% to 5% weight loss thats difficult to maintain long-term
Generally, gastrointestinal adverse events were mild to moderate, mostly occurred during dose titration, and often resolved over time
What to Ask at the Follow-Up Reasonable follow-up questions include how tolerability will be assessed, what symptoms warrant a call rather than waiting, how progress will be measured beyond weight, and what the plan is if the response is smaller than hoped